Joshua Meier

Jack Dent and Joshua Meier, co-founders of Chai Discovery, share their groundbreaking work on the Chai-2 model, revolutionizing antibody design with a remarkable 20% success rate. They discuss how AI can optimize complex molecular properties, reshaping the landscape of drug discovery. The duo emphasizes the importance of structure prediction and offers insights into how biotech professionals can leverage this innovative technology. Tune in to hear their vision for the future of drug development and the skills bioscientists should embrace to thrive in this evolving field.

Joshua Meier, co-founder of Chai Discovery and ex-Chief AI Officer at Absci, shares insights on the groundbreaking role of AI in drug discovery. He discusses how the field has evolved, achieving unprecedented success rates. The conversation reveals how AI models differ from human chemists and the strategic choices behind open-sourcing foundational models. Meier also highlights Chai 2's innovative capabilities in testing biological hypotheses and the promising future of AI in revolutionizing therapeutic development and enhancing pharmaceutical innovation.

This discussion features Will Brown, who delves into Meta's aggressive recruitment strategies to dominate the AI landscape, while Will O'Brien shares insights on autonomous underwater vehicles that can restore seagrass efficiently. Tom Lee talks about BitMine's cryptocurrency ventures, and Joshua Meier unveils Chai Discovery's innovative model to accelerate drug development. John Glasgow wraps up the conversation, highlighting Campfire's AI-driven approach to finance, showcasing technology's transformative power across various sectors.

Joshua Meier, co-founder and CEO of Chai Discovery and former Chief AI Officer at Absci, dives into the transformative role of AI in drug discovery. He explains the evolution through three waves of AI, achieving success rates once deemed impossible. The conversation reveals how AI models think differently from human chemists and the implications of open-sourcing foundational models. Joshua highlights the creativity of AI in generating solutions and discusses key milestones that could redefine the future of pharmaceuticals and biotech.

Joshua Meier, co-founder of Chai Discovery and former researcher at OpenAI and Meta, applies large-scale AI to protein and molecule design. He talks about Chai’s molecule-design platform and rapid lab success improvements. Conversations cover partnerships with big pharma, scaling compute and data, and how AI is unlocking previously undruggable biology.